| Literature DB >> 26801083 |
Clémence Leyrat1,2,3,4, Agnès Caille5,6,7,8, Yohann Foucher9, Bruno Giraudeau5,6,7,8.
Abstract
BACKGROUND: Despite randomization, baseline imbalance and confounding bias may occur in cluster randomized trials (CRTs). Covariate imbalance may jeopardize the validity of statistical inferences if they occur on prognostic factors. Thus, the diagnosis of a such imbalance is essential to adjust statistical analysis if required.Entities:
Mesh:
Year: 2016 PMID: 26801083 PMCID: PMC4724161 DOI: 10.1186/s12874-015-0100-4
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Standardized differences
| Baseline groups comparability for each covariate can be assessed with the standardized difference [ |
|
|
| where |
|
|
| where |
Patient baseline characteristics per group in the study on management of osteoarthritis with a standardized evaluation tool (first motivating example)
| Characteristics | Control | Standardized tool |
| SDiff (%) |
|---|---|---|---|---|
|
|
| |||
|
|
| |||
| Duration of symptoms (months) | 68.0 (69.8) | 70.9 (75.0) | 0.2737 | 4.03 |
| Age (years) | 67.2 (9.7) | 66.4 (10.0) |
| 7.81 |
| BMI (kg.m −2) | 27.8 (4.9) | 27.7 (4.7) | 0.3824 | 3.14 |
| Patient global assessment (0-100) | 61.1 (18.2) | 56.7 (17.4) |
| 24.44 |
| Pain evaluation VAS (0-100) | 59.4 (16.0) | 55.3 (15.1) |
| 26.32 |
| WOMAC function score (0-100) | 45.5 (16.3) | 43.8 (16.0) |
| 10.32 |
|
|
| |||
| Osteoarthritis in other joints | 1366 (91.4) | 1311 (89.7) | 0.1297 | 5.81 |
| Prior treatment | ||||
| IA treatment | 434 (29.0) | 432 (29.6) | 0.7877 | 1.14 |
| NSAIDs | 955 (63.9) | 958 (65.5) | 0.3689 | 3.45 |
| SYSADOA | 617 (41.3) | 605 (41.4) | 0.9810 | 0.22 |
| Male | 424 (28.4) | 459 (31.4) | 0.0782 | 6.65 |
| Kellgren and Lawrence grade | 0.2594 | |||
| III | 724 (48.4) | 677 (46.3) | 4.25 | |
| IV | 516 (34.5) | 547 (37.4) | 6.02 |
BMI: Body Mass Index; VAS: Visual Analogue Scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index; IA: intra-articular; NSAID: non-steroidal anti-inflammatory drug; SYSADOA: systematic slow acting drug for osteoarthritis. SDiff: standardized difference; p: p-value for univariate tests (adjusted t test for quantitative variables, adjusted chi-square test for qualitative variables to take the clustering into account). Bold values are significant tests at a 5 % significance level
Patient baseline characteristics per group in the study on standardized consultation for patients with osteoarthritis of the knee (second motivating example)
| Characteristics | Control | Standardized consultation |
| SDiff (%) |
|---|---|---|---|---|
|
|
| |||
|
|
| |||
| Age (years) | 64.5 (8.4) | 63.9 (8.1) | 0.4720 | 8.02 |
| Weight (kg) | 81.4 (13.6) | 84.1 (12.9) | 0.0665 | 20.60 |
| BMI (kg.m −2) | 30.2 (3.8) | 31.2 (3.5) |
| 27.63 |
| PEL (0-5) | 2.2 (0.9) | 2.2 (0.8) | 0.9594 | 0.00 |
| Delay since beginning of pain (years) | 5.5 (5.9) | 7.4 (7.5) |
| 27.57 |
| Age at beginning of pain (years) | 59.1 (10.4) | 56.5 (10.5) |
| 24.28 |
| Pain (0-10) | 5.6 (1.3) | 5.5 (1.2) | 0.3646 | 10.38 |
| WOMAC function score (0-100) | 29.9 (12.2) | 30.3 (11.7) | 0.7377 | 3.76 |
| SF-12 physical subscale | 34.8 (6.7) | 35.4 (6.7) | 0.4385 | 8.70 |
| SF-12 mental subscale | 41.4 (9.4) | 43.3 (10.1) | 0.0827 | 19.31 |
| Global assessment of disease status (0-10) | 5.6 (1.5) | 5.6 (1.5) | 0.9133 | 1.31 |
|
|
| |||
| Male | 49 (27.1) | 34 (23.3) | 0.5132 | 8.73 |
| Prior treatments | ||||
| Analgesics | 130 (71.8) | 96 (65.8) | 0.2889 | 13.13 |
| NSAIDs | 95 (52.5) | 90 (61.6) | 0.1215 | 18.58 |
| Current use of NSAIDS | 160 (88.4) | 126 (86.3) | 0.6883 | 6.31 |
| SYSADOA | 74 (40.9) | 68 (46.6) | 0.3576 | 11.49 |
| Current use of SYSADOA | 179 (98.9) | 145 (99.3) | 1.0000 | 4.46 |
| IA treatment | 31 (17.1) | 29 (19.9) | 0.6229 | 7.05 |
| Non-drug treatment | 110 (60.8) | 71 (48.6) |
| 24.58 |
| Diet | 49 (27.1) | 31 (21.2) | 0.2750 | 13.67 |
| Dietetician | 12 (6.6) | 7 (4.8) | 0.6401 | 7.91 |
| Physical exercice | 44 (24.3) | 27 (18.5) | 0.2571 | 14.22 |
| Physiotherapy | 30 (16.6) | 17 (11.6) | 0.2692 | 14.20 |
| Knee orthosis | 21 (11.6) | 11 (7.5) | 0.2967 | 13.86 |
| Insoles | 24 (13.3) | 11 (7.5) | 0.1376 | 18.84 |
| Walking sticks | 13 (7.2) | 10 (6.8) | 1.0000 | 1.30 |
BMI: Body Mass Index; PEL: Baecke’s physical exercice level scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index; SF-12: 12-items Short Form; IA: intra-articular; NSAID: non-steroidal anti-inflammatory drug; SYSADOA: systematic slow acting drug for osteoarthritis. SDiff: standardized difference; p: p-value for univariate tests (adjusted t test for quantitative variables, adjusted chi-square test for qualitative variables to take the clustering into account). Bold values are significant tests at a 5 % significance level
Fig. 1Percentage of imbalance detection π as a function of the number of baseline covariates r, the sample size per arm n, the standardized difference (SD) for unbalanced covariates and the percentage of unbalanced covariates 100×s/r. Results were pooled over the number of clusters per arm k. Five thousand simulations were performed per scenario
Fig. 2Percentage of imbalance detection π ′ after covariate pre-selection as a function of the initial percentage of imbalance detection π. Each point corresponds to a different number of covariates. The gray line is the first bisector. Five thousand simulations were performed per scenario
Fig. 3Steps for bias detection and guidance for covariates adjustment. Our diagnosis tool corresponds to the top part of the graph (part 1), whereas the bottom part (part 2) is a qualitative approach to help to perform a covariate adjustment. Part 2 has to be thought in accordance to clinical knowledge about potential confounders. *Adjustment on predictors can increase precision in linear model and generally increases power in case of chance imbalance